#BEGIN_DRUGCARD DB01051

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Oral bioavailability is negligible.

# Biotransformation:
Not Available

# Brand_Mixtures:
Albacillin Suspension (Novobiocin (Novobiocin Sodium) + Penicillin G Procaine)
Delta-Albaplex Tablets (Novobiocin (Novobiocin Sodium) + Prednisolone + Tetracycline Hydrochloride)
Novodry Plus Suspension (Novobiocin (Novobiocin Sodium) + Penicillin G Procaine)
Special Formula 17900-Forte Suspension (Dihydrostreptomycin (Dihydrostreptomycin Sulfate) + Hydrocortisone Acetate + Hydrocortisone Sodium Succinate + Novobiocin (Novobiocin Sodium) + Penicillin G Procaine + Polymyxin B Sulfate)

# Brand_Names:
Albamix
Albamycin
Cardelmycin
Cathocin
Cathomycin
Inamycin
Novo-R
Robiocina
Sirbiocina
Spheromycin
Stilbiocina
Streptonivicin

# CAS_Registry_Number:
303-81-1

# ChEBI_ID:
Not Available

# Chemical_Formula:
C31H36N2O11

# Chemical_IUPAC_Name:
(3R,4S,5R,6R)-5-hydroxy-6-[(4-hydroxy-3-{[4-hydroxy-3-(3-methylbut-2-en-1-yl)benzene]amido}-8-methyl-2-oxo-2H-chromen-7-yl)oxy]-3-methoxy-2,2-dimethyloxan-4-yl carbamate

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
An antibiotic compound derived from Streptomyces niveus. It has a chemical structure similar to coumarin. Novobiocin binds to DNA gyrase, and blocks adenosine triphosphatase (ATPase) activity.  (From Reynolds, Martindale The Extra Pharmacopoeia, 30th ed, p189) [PubChem]

# Dosage_Forms:
Injection, powder, for solution	Intravenous

# Drug_Category:
Anti-Bacterial Agents
Enzyme Inhibitors
Nucleic Acid Synthesis Inhibitors

# Drug_Interactions:
Not Available

# Drug_Reference:
13303117	DAVID NA, BURGNER PR: Clinical effectiveness and safety of novobiocin. Antibiotic Med Clin Ther. 1956 Apr;2(4):219-29.
13425410	CORBIN EE, PRIGOT A: Novobiocin; absorption, diffusion, and excretion studies. Antibiot Annu. 1956-1957;:392-5.
15811527	Singh G, Jayanarayan KG, Dey CS: Novobiocin induces apoptosis-like cell death in topoisomerase II over-expressing arsenite resistant Leishmania donovani. Mol Biochem Parasitol. 2005 May;141(1):57-69.
17132020	Burlison JA, Neckers L, Smith AB, Maxwell A, Blagg BS: Novobiocin: redesigning a DNA gyrase inhibitor for selective inhibition of hsp90. J Am Chem Soc. 2006 Dec 6;128(48):15529-36.
17876001	Vickers AA, Chopra I, O'neill AJ: Intrinsic novobiocin resistance in Staphylococcus saprophyticus. Antimicrob Agents Chemother. 2007 Sep 17;.

# Drug_Type:
Approved
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
4.1

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Insoluble

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Novobiocin

# HET_ID:
NOV

# Half_Life:
6 hours

# InChI_Identifier:
InChI=1S/C31H36N2O11/c1-14(2)7-8-16-13-17(9-11-19(16)34)27(37)33-21-22(35)18-10-12-20(15(3)24(18)42-28(21)38)41-29-23(36)25(43-30(32)39)26(40-6)31(4,5)44-29/h7,9-13,23,25-26,29,34-36H,8H2,1-6H3,(H2,32,39)(H,33,37)/t23-,25+,26-,29-/m1/s1

# InChI_Key:
InChIKey=YJQPYGGHQPGBLI-KGSXXDOSSA-N

# Indication:
For the treatment of infections due to staphylococci and other susceptible organisms

# KEGG_Compound_ID:
C05080

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
1051

# Mechanism_Of_Action:
Novobiocin is an aminocoumarin. Aminocoumarins are very potent inhibitors of bacterial DNA gyrase and work by inhibiting the GyrB subunit of the enzyme involved in energy tranduction. Novobiocin as well as the other aminocoumarin antibiotics act as competitive inhibitors of the ATPase reaction catalysed by GyrB.

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
612.6243

# Molecular_Weight_Mono:
612.231910004

# Organisms_Affected:
Enteric bacteria and other eubacteria

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA164768819

# Pharmacology:
Novobiocin is an aminocoumarin antibiotic that was produced by the actinomycete <i>Streptomyces niveus</i>. Novobiocin binds to DNA gyrase, and blocks adenosine triphosphatase (ATPase) activity. Other antibiotics in the aminocoumarin class include coumermycin A1 and clorobiocin.

# Predicted_LogP_Hydrophobicity:
3.07

# Predicted_LogS:
-4.8

# Predicted_Water_Solubility:
9.66e-03 g/l

# Primary_Accession_No:
DB01051

# Protein_Binding:
95%

# PubChem_Compound_ID:
9346

# PubChem_Substance_ID:
46507250

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
APRD00694

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
CO[C@@H]1[C@@H](OC(N)=O)[C@@H](O)[C@H](OC2=C(C)C3=C(C=C2)C(O)=C(NC(=O)C2=CC=C(O)C(CC=C(C)C)=C2)C(=O)O3)OC1(C)C

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Antibiotic Pa-93
Crystallinic Acid
NOV
Novobiocina [INN-Spanish]
Novobiocine [INN-French]
Novobiocinum [INN-Latin]

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:19:52 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Novobiocin

# pKa_Isoelectric_Point:
4.3

# Drug_Target_1_Cellular_Location:
Cytoplasmic

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
8231802	Maxwell A: The interaction between coumarin drugs and DNA gyrase. Mol Microbiol. 1993 Aug;9(4):681-6.
8664301	Gormley NA, Orphanides G, Meyer A, Cullis PM, Maxwell A: The interaction of coumarin antibiotics with fragments of DNA gyrase B protein. Biochemistry. 1996 Apr 16;35(15):5083-92.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
X71437

# Drug_Target_1_GenBank_ID_Protein:
Not Available

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
gyrB

# Drug_Target_1_Gene_Sequence:
>1935 bp
ATGGTGACTGCATTGTCAGATGTAAACAACACGGATAATTATGGTGCTGGGCAAATACAA
GTATTAGAAGGTTTAGAAGCAGTACGTAAAAGACCAGGTATGTATATAGGATCGACTTCA
GAGAGAGGTTTGCACCATTTAGTGTGGGAAATTGTCGATAATAGTATCGATGAAGCATTA
GCTGGTTATGCAAATCAAATTGAAGTTGTTATTGAAAAAGATAACTGGATTAAAGTAACG
GATAACGGACGTGGTATCCCAGTTGATATTCAAGAAAAAATGGGACGTCCAGCTGTCGAA
GTTATTTTAACTGTTTTACATGCTGGTGGTAAATTCGGCGGTGGCGGATACAAAGTATCT
GGTGGTTTACATGGTGTTGGTTCATCAGTTGTAAACGCATTGTCACAAGACTTAGAAGTA
TATGTACACAGAAATGAGACTATATATCATCAAGCATATAAAAAAGGTGTACCTCAATTT
GACTTAAAAGAAGTTGGCACAACTGATAAGACAGGTACTGTCATTCGTTTTAAAGCAGAT
GGAGAAATCTTCACAGAGACAACTGTATACAACTATGAAACATTACAGCAACGTATTAGA
GAGCTTGCTTTCTTAAACAAAGGAATTCAAATCACATTAAGAGATGAACGTGATGAAGAA
AACGTTAGAGAAGACTCCTATCACTATGAGGGCGGTATTAAATCTTATGTTGAGTTATTG
AACGAAAATAAAGAACCTATTCATGATGAGCCAATTTATATTCATCAATCTAAAGATGAT
ATTGAAGTAGAAATTGCGATTCAATATAACTCAGGATATGCCACAAATCTTTTAACTTAC
GCAAATAACATTCATACGTACGAAGGTGGTACGCATGAAGACGGATTTAAACGTGCATTA
ACGCGTGTCTTAAATAGTTATGGTTTAAGTAGCAAGATTATGAAAGAAGAAAAAGATAGA
CTTTCTGGTGAAGATACACGTGAAGGTATGACAGCAATTATATCTATCAAACATGGTGAT
CCTCAATTCGAAGGTCAAACGAAGACAAAATTAGGTAATTCTGAAGTGCGTCAAGTTGTA
GATAAATTATTCTCAGAGCACTTTGAACGATTTTTATATGAAAATCCACAAGTCGCACGT
ACAGTGGTTGAAAAAGGTATTATGGCGGCACGTGCACGTGTTGCTGCGAAAAAAGCGCGT
GAAGTTACACGTCGTAAATCAGCGTTAGATGTAGCAAGTCTTCCAGGTAAATTAGCCGAT
TGCTCTAGTAAAAGTCCTGAAGAATGTGAGATATTCTTAGTCGAAGGGGACTCTGCTGGG
GGGTCTACAAAATCTGGTCGTGACTCTAGAACGCAGGCGATTTTACCATTACGAGGTAAG
ATATTAAATGTTGAAAAAGCACGATTAGATAGAATTTTGAATAACAATGAAATTCGTCAA
ATGATCACAGCATTTGGTACAGGAATTGGTGGCGACTTTGATCTAGCGAAAGCAAGATAT
CACAAAATCGTCATTATGACTGATGCCGATGTGGATGGAGCGCATATTAGAACATTGTTA
TTAACATTCTTCTATCGATTTATGAGACCGTTAATTGAAGCAGGCTATGTGTATATTGCA
CAGCCACCGTTGTATAAACTGACACAAGGTAAACAAAAGTATTATGTATACAATGATAGG
GAACTTGATAAACTTAAATCTGAATTGAATCCAACACCAAAATGGTCTATTGCACGATAC
AAAGGTCTTGGAGAAATGAATGCAGATCAATTATGGGAAACAACAATGAACCCTGAGCAC
CGTGCTCTTTTACAAGTAAAACTTGAAGATGCGATTGAAGCGGACCAAACATTTGAAATG
TTAATGGGTGACGTTGTAGAAAACCGTAGACAATTTATAGAAGATAATGCAGTTTATGCA
AACTTAGACTTCTAA

# Drug_Target_1_General_Function:
Involved in ATP binding

# Drug_Target_1_General_References:
1311298	Margerrison EE, Hopewell R, Fisher LM: Nucleotide sequence of the Staphylococcus aureus gyrB-gyrA locus encoding the DNA gyrase A and B proteins. J Bacteriol. 1992 Mar;174(5):1596-603.
2160946	Hopewell R, Oram M, Briesewitz R, Fisher LM: DNA cloning and organization of the Staphylococcus aureus gyrA and gyrB genes: close homology among gyrase proteins and implications for 4-quinolone action and resistance. J Bacteriol. 1990 Jun;172(6):3481-4.
7811012	Ito H, Yoshida H, Bogaki-Shonai M, Niga T, Hattori H, Nakamura S: Quinolone resistance mutations in the DNA gyrase gyrA and gyrB genes of Staphylococcus aureus. Antimicrob Agents Chemother. 1994 Sep;38(9):2014-23.
7898435	Alonso JC, Fisher LM: Nucleotide sequence of the recF gene cluster from Staphylococcus aureus and complementation analysis in Bacillus subtilis recF mutants. Mol Gen Genet. 1995 Mar 20;246(6):680-6.
8388872	Brockbank SM, Barth PT: Cloning, sequencing, and expression of the DNA gyrase genes from Staphylococcus aureus. J Bacteriol. 1993 Jun;175(11):3269-77.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
4150

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
72541

# Drug_Target_1_Name:
DNA gyrase subunit B

# Drug_Target_1_Number_of_Residues:
644

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00204	DNA_gyraseB
PF00986	DNA_gyraseB_C
PF01751	Toprim
PF02518	HATPase_c

# Drug_Target_1_Protein_Sequence:
>DNA gyrase subunit B
MVTALSDVNNTDNYGAGQIQVLEGLEAVRKRPGMYIGSTSERGLHHLVWEIVDNSIDEAL
AGYANQIEVVIEKDNWIKVTDNGRGIPVDIQEKMGRPAVEVILTVLHAGGKFGGGGYKVS
GGLHGVGSSVVNALSQDLEVYVHRNETIYHQAYKKGVPQFDLKEVGTTDKTGTVIRFKAD
GEIFTETTVYNYETLQQRIRELAFLNKGIQITLRDERDEENVREDSYHYEGGIKSYVELL
NENKEPIHDEPIYIHQSKDDIEVEIAIQYNSGYATNLLTYANNIHTYEGGTHEDGFKRAL
TRVLNSYGLSSKIMKEEKDRLSGEDTREGMTAIISIKHGDPQFEGQTKTKLGNSEVRQVV
DKLFSEHFERFLYENPQVARTVVEKGIMAARARVAAKKAREVTRRKSALDVASLPGKLAD
CSSKSPEECEIFLVEGDSAGGSTKSGRDSRTQAILPLRGKILNVEKARLDRILNNNEIRQ
MITAFGTGIGGDFDLAKARYHKIVIMTDADVDGAHIRTLLLTFFYRFMRPLIEAGYVYIA
QPPLYKLTQGKQKYYVYNDRELDKLKSELNPTPKWSIARYKGLGEMNADQLWETTMNPEH
RALLQVKLEDAIEADQTFEMLMGDVVENRRQFIEDNAVYANLDF

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
DNA gyrase negatively supercoils closed circular double- stranded DNA in an ATP-dependent manner and also catalyzes the interconversion of other topological isomers of double-stranded DNA rings, including catenanes and knotted rings

# Drug_Target_1_SwissProt_ID:
P0A0K8

# Drug_Target_1_SwissProt_Name:
GYRB_STAAU

# Drug_Target_1_Synonyms:
EC 5.99.1.3

# Drug_Target_1_Theoretical_pI:
5.68

# Drug_Target_1_Transmembrane_Regions:
None

#END_DRUGCARD DB01051
